1	Cost-utility analysis of primary HPV testing through home-based self-sampling in
2	comparison to visual inspection using acetic acid for cervical cancer screening in
3	East district, Sikkim, India, 2023
4	
5 6 7 8	Roopa Hariprasad ¹ , Bhavani Shankara Bagepally ^{2**} , Sajith Kumar ² , Sangeeta Pradhan ³ , Deepsikka Gurung ³ , Harki Tamang ³ , Arpana Sharma ⁴ , Tarun Bhatnagar ^{1*}
9 10 11 12	¹ School of Public Health, Indian Council Medical Research-National Institute of Epidemiology, Chennai, Tamil Nadu, India
13 14 15	² Health Technology Assessment Resource Centre, Indian Council Medical Research- National Institute of Epidemiology, Chennai, Tamil Nadu, India
16 17	³ Department of Health and Welfare, Government of Sikkim, Gangtok, Sikkim, India
18 19 20	⁴ Jhpiego - an affiliate of Johns Hopkins University, Gangtok, Sikkim, India
21 22 23 24	* Corresponding author E-mail: <u>drtarunb@gmail.com</u> (TB)
25 26 27 28	** Co-Corresponding author E-mail: <u>bshankara@gmail.com</u> (BSB)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 Abstract

30 Introduction

Primary Human Papilloma Virus (HPV) testing offers higher sensitivity and specificity over Visual Inspection using Acetic acid (VIA) in cervical cancer screening. Self-sampling is a promising strategy to boost participation and reduce disparities. However, concerns about the initial costs hinder HPV testing adoption in low and middle-income countries. This study assesses the cost-utility of home-based HPV self-sampling versus VIA for cervical cancer screening in India

37

38 Methods

A cross-sectional study was conducted in East district, Sikkim, India, comparing the 39 costs and utility outcomes of population-based cervical cancer screening through VIA 40 41 and primary HPV screening through self-sampling. Cost-related data were collected from April 2021 to March 2022 using the bottom-up micro-costing method, while 42 utility measures were collected prospectively using the EuroQoL-5D-5L 43 44 questionnaire. The utility values were converted into quality-adjusted life days (QALDs) for an 8-day period. The willingness to pay threshold (WTP) was based on 45 46 per capita GDP for 2022. . If the calculated Incremental Cost-Effectiveness Ratio (ICER) value is lower than the WTP threshold, it signifies that the intervention is 47 cost-effective. 48

49

50 **Results**

The study included 95 women in each group of cervical cancer screening with VIA & HPV self-sampling. For eight days, the QALD was found to be 7.977 for the VIA group and 8.0 for the HPV group. The unit cost per woman screened by VIA and

54	HPV self-testing was ₹1,597 (US\$ 19.2) and ₹1,271(US\$ 15.3), respectively. The
55	ICER was ₹-14,459 (US\$ -173.6), which was much below the WTP threshold for
56	eight QALDs, i.e. ₹ 4,193 (US\$ 50.4).
57	
58	Conclusion
59	The findings support HPV self-sampling as a cost-effective alternative to VIA. This
60	informs policymakers and healthcare providers for better resource allocation in
61	cervical cancer screening in Sikkim.
62	
63	Key words: Cervical cancer screening, Cost-utility analysis, Primary Human
64	Papilloma Virus (HPV) testing, Self-sampling, Visual Inspection using Acetic acid
65	(VIA), EuroQoL-5D-5L
66	

67 Introduction

Cervical cancer ranks as the second most prevalent cancer among women in India. 68 Globocan estimates for 2020 showed 123,907 incident cases, and 77,348 cases 69 succumbed to this disease [1]. In 2016, the Government of India, through the Ministry 70 71 of Health and Family Welfare, implemented an operational framework with the goal of facilitating the screening and early detection of three preventable cancers: oral, 72 73 breast, and cervical cancer [2]. Although visual inspection using the acetic acid (VIA) screening method adopted in the program for cervical cancer is evidence-based, there 74 are concerns about the feasibility of its implementation in the field and beneficiary 75 satisfaction [3,4]. Further, Human Papilloma Virus (HPV) testing exhibits higher 76 sensitivity (98%) and specificity (90.6%) than VIA [sensitivity 31.6% and specificity 77 87.5%][5]. 78

In accordance with World Health Organization's (WHO) recommendation, high-79 income countries have transitioned from cytology-based screening to primary HPV 80 testing [6]. Research has demonstrated that self-collected samples for HPV testing by 81 women yield comparable results to clinician-collected cervical samples [7,8]. 82 Nevertheless, the implementation of HPV programs in low- and middle-income 83 84 countries is hindered by the upfront financial burden associated with the adoption of this approach despite its evident advantages over VIA. A systematic review on the 85 cost-effectiveness of all cervical cancer screening methods in low- and middle-86 income countries revealed that HPV testing through self-sampling is the most cost-87 effective to screen cervical cancer [9]. In the context of India, a single modeling study 88 has examined the cost-effectiveness of three cervical cancer screening strategies: 89 90 VIA, Pap smear, and HPV DNA [10]. However, to obtain more precise and 91 trustworthy insights, empirical data is required. By utilizing real-world data, we can

gather more reasonable information on the actual costs, effectiveness, and outcomes
 of cervical cancer prevention strategies when implemented within the Indian
 healthcare system. Such empirical studies are crucial for enhancing the applicability
 and validity of findings, empowering policymakers to make well-informed decisions
 regarding resource allocation for cervical cancer prevention programs in India.

- Sikkim, a northeastern state in India, has piloted primary HPV screening through self-97 98 sampling in the East district to explore the challenges in implementation and planning to scale up to all districts based on the results and availability of funds for the same. 99 100 In order to consider HPV testing as the primary screening of cervical cancer in the State, a detailed economic analysis using contextual data is needed. An essential 101 factor in evaluating the validity of a new screening program is its ability to 102 demonstrate economic efficiency while also surpassing the physical, psychological, 103 and societal harms stemming from the associated testing and screening procedures. 104 Thus, the current study was planned to assess the cost-utility of home-based HPV 105 self-sampling compared to VIA for cervical cancer screening among women over 30 106 years in the East district of Sikkim state. 107
- 108

109 Methods

110 **S**1

Study design and setting

We did a cross-sectional study in the East district, Sikkim, India, in which cost-related data was collected retrospectively, while the data for utility measures was collected prospectively. Fig 1 illustrates the study workflow. It includes estimates on the cost of population-based cervical cancer screening through VIA (facility-based) under the National Program for Prevention and Control of Non-Communicable Diseases (NP-NCD) program and primary HPV screening through self-sampling (home-based)

from a disaggregated societal perspective. This perspective considers costs estimated
at both the health provider/system level and the individual level, specifically focusing
on the direct expenses borne by women undergoing screening in the form of out-ofpocket payments.

- 121 Fig 1: Illustration of the Study Work Flow
- 122

123 Under the NP-NCD, VIA is performed on the eligible population (women aged 30 years and older) by the Community Health Officer (CHO) at Health and Wellness 124 125 Centres (HWCs). If they are found to be VIA positive, women are referred to PHC for confirmation by Primary Health Centre (PHC) Medical Officer. In the primary 126 HPV screening group, Accredited Social Health Activists (ASHAs) provide the 127 sampling kits to women when they make home visits for either filling Community 128 Based Assessment Checklist (CBAC) or Reproductive and Child Health (RCH) 129 program-related activities. Community Health Workers in India are referred to as 130 ASHAs. They are equipped with Information Education and Communication (IEC) 131 materials, such as charts and videos, which demonstrate the correct procedure for 132 collecting vaginal samples. The woman then collects the sample herself and hands 133 over the sampler kit back to ASHA. The sample is transported to the HPV lab at the 134 district hospital from PHC in an ambulance, which does a weekly visit to District 135 Hospital for transportation of other contingencies like vaccines and medicines. 136

The detailed flow of the screening process in both groups is provided in Fig A of the supplementary file. The activities in both groups are the same once the woman is referred to PHC after screening. Hence, the unit cost is calculated only up to the screening process. Participants' eligibility criteria for calculating the utility values were as follows; women aged 30 years or older who underwent screening using VIA

at HWCs by CHOs, and women aged 30 years or above who underwent screening
using HPV self-sampling at home were included in the study. Women who declined
to provide consent were not included in the study. The reference period for costing
was from April 2021 to March 2022.

- Considering the mean EuroQol-5 dimension score (SD) of women after cervical 146 cancer screening by VIA to be 0.89 (0.19) and the mean EQ-5D-5L score (SD) of 147 148 women after HPV self-sampling to be 0.98 (0.19) [11] and power as 85%, alpha as 5% (two-sided), we calculated a sample size of 81 women in each group. Adjusting 149 150 for a 15% attrition rate, the sample size was calculated to be 95 women in VIA and HPV groups. East district of Sikkim consists of eight PHCs (Two urban and six rural) 151 and forty-three health and wellness centres (HWCs). HPV self-sampling (home-152 based) is implemented by the state govt in the East district in three PHC catchment 153 areas (two urban and one rural). These HWCs selected for HPV screening do not 154 perform VIA screening anymore. Out of the remaining thirty-two HWCs in the 155 district, the best performing eleven HWCs in terms of number of women screened by 156 VIA were selected. 157
- 158 Data collection-costs

For cost analysis, costing related to human resources, space/building, furniture, equipment, consumables, IEC Material, stationery and overheads for both screening methods was obtained. Utility measures were calculated using EQ-5D-5L scores.

162 Cost analysis in this study was undertaken using a bottom-up approach of micro-163 costing methods. All costs were reported for the reference year 2022 (financial year 164 April 2021 to March 2022). All the resources used in screening for cervical cancer 165 using VIA and HPV were identified, measured and valued. Data on capital and 166 recurrent resources utilised to deliver cervical cancer screening services during the

reference year were considered. Costing related to space/building, human resources,
 furniture, equipment, consumables, IEC Material, stationery and overheads for both
 screening methods were obtained from records and the data of the same were
 accesssed between 15th January 2023 to 30th April 2023.

For estimating the building cost, the current market rental price of a similar space through three key informant interviews was collected for each of the eleven HWCs and the HPV laboratory. The average of the three rental prices was considered. To allocate the cost specifically to the VIA screening activity, an apportioning factor was calculated considering the working time dedicated to VIA screening in a year relative to the total working hours of the healthcare facility.

To estimate the human resources cost, the investigator interviewed the study participants and healthcare persons using a structured questionnaire. The information related to salary/wages, perks and time spent on each of the activities of screening were collected. The human resources costs associated with screening were calculated using the apportioning factor derived from the time spent on activities.

The consumable cost was assessed using the cost, quantity and procurement date of 182 consumables procured during the reference period for VIA and HPV tests by the state 183 central procurement division. The details were obtained from their stock register and 184 accounts division. For women screened by VIA, the Out of Pocket Expenditure 185 (OOPE) accounted for direct costs associated with transportation to the facility, as 186 well as any food expenses incurred during the screening period for both the women 187 and their attendants, if accompanied. However, in the HPV group, it was not 188 applicable as screening took place at home. The cost of overheads like water, 189 maintenance, the electricity of HWCs and HPV testing lab was obtained at the facility 190 191 level. The total annual cost incurred by each group was calculated by summing up

the costs associated with various components. Unit cost was calculated by dividing
the total cost of screening by the number of individuals screened in each group as
unit cost per woman screened by VIA and unit cost per woman screened by HPV
self-sampling

Data collection-utility

EQ-5D-5L questionnaire was used for the personal interview [12]. Permission to use 197 the paper, telephonic, and digital versions has been obtained from the EuroQol office. 198 The questionnaire has five dimensions graded across five levels of problems. The 199 tool comprises a descriptive questionnaire along with a visual analog scale (VAS) to 200 assess perceived problems. These problem levels were assigned numerical codes 201 202 ranging from 1 to 5, with each state represented by a 5-digit code. The questionnaire encompasses five dimensions, namely mobility, self-care, usual activities, 203 pain/discomfort, and anxiety/depression, and investigates five problem levels, 204 205 including the absence of problems, minor problems, moderate problems, significant problems, and extreme difficulties or inability to perform. 206

EQ-5D-5L was administered to all the Women undergoing cervical cancer screening 207 by VIA at HWCs as well as women undergoing cervical cancer screening at home by 208 HPV self-sampling between the period 15th January 2023 to 30th April 2023. Cervical 209 cancer screening by VIA is performed at HWCs by trained CHOs as a part of the 210 ongoing NP-NCD program. The questionnaire was administered after the screening 211 procedure is complete and before the CHO informs the VIA result to the woman. For 212 women undergoing HPV self-testing at home, it was administered after she collected 213 the sample. 214

Permission from women to contact her telephonically after eight days was taken in
the consent form. The EQ-5D-5L questionnaire was administered telephonically on

the 8th day of screening, and the status of symptoms was collected as per the
satisfaction questionnaire.

Data analysis

220 Scoring in EQ-5D-5L and calculation of QALD for 8 eight days

The EO-5D-5L questionnaire responses from study participants were converted into 221 a single index value using India-specific tariff values. This conversion process 222 considered the health-related quality of life (HRQoL) across all five dimensions 223 (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and 224 assigned a weighted value to each health state. Once the EQ-5D-5L index value was 225 obtained for each individual, it was multiplied by 8 (duration of interest) to calculate 226 227 the QALDs. This calculation combines the individual's health state utility value with 228 the duration, reflecting the overall quality of life experienced during that period. The EQ-5D-5L VAS scale assesses the self-evaluated quality of life on a scale of 1 (worst 229 230 imaginable health state) to 100 (best imaginable health state). Median quality of life with interquartile range was reported. 231

232 Utility score

An EQ-5D-5L summary index was calculated by deducting the appropriate weights from 1, the value for full health (i.e., state 11111). For estimating the quality-of-life utility values, health states generated from the scoring on the EQ-5D-5L descriptive system was converted into utility scores using the India's value set [13] (which is a collection of index values (weights) for all possible EQ-5D-5L states) was used for estimating the utility score.

Incremental Cost-Effectiveness Ratio (ICER)

As per WHO guidance, the Willingness to Pay (WTP) threshold was determined
based on the per capita GDP for the year 2022, amounting to ₹ 1,91,288 (US\$ -

242 2297.7) per QALY. Then, for an eight (days period) QALDs, the WTP of ₹ 4193
243 (US\$ 50.4) was considered. The Incremental Cost-Effectiveness Ratio (ICER) was
244 then computed by dividing the difference in costs (incremental cost) between the two
245 groups by the difference in the QALD8 scores. If the calculated ICER value is lower
246 than the WTP threshold, it signifies that the intervention is cost-effective.

247 Uncertainty analysis

A one-way sensitivity analysis was conducted to examine the effects of varying the number of individuals screened using both HPV & VIA methods. Additionally, the analysis included adjustments of all cost components with 10% and 25% variations, and the results were graphically presented.

Scenario analysis was performed to evaluate the potential impacts of different testing facility settings, including rural or urban locations. Furthermore, the analysis considered the reduction in HPV cost resulting from competitive pricing offered by manufacturers. We also explored the scenarios, where a healthcare provider at the facility conducted HPV testing, as well as the option of self-sampling at the facility.

257 Statistical analysis was done using Epi-info version 7.2.1.0

All the costs are reported both in Indian National Rupees (INR) -₹ and United States

259 Dollar (US\$) (1 US\$ = \gtrless 83.2526). (https://www.exchangerates.org.uk/USD-INR-16_08_2023-

260 exchange-rate-history.html)

261

Ethical approval

Study proposal was approved by the Institute Human Ethics Committee of the ICMR-National Institute of Epidemiology, Chennai, India (Reference number: NIE/IHEC/A/202212-02). All the respondents were interviewed after obtaining written informed consent.

267 **Results**

The baseline and screening attributes of women (95 in each group) interviewed in the 268 VIA and HPV screening group are provided in Table 1. Both the HPV group and the 269 VIA group were comparable in terms of age distributions, marital status, educational 270 271 status, parity and age at first intercourse. However, there was a significant disparity in residence patterns, with VIA consisting of a higher proportion (99%) of 272 273 participants residing in rural areas, while HPV predominantly comprised individuals living in urban regions (84%). There was a notable distinction in occupational 274 profiles that emerged, with a greater proportion of homemakers (70%) observed in 275 276 the VIA group, while the HPV testing group exhibited a more diverse range of occupations. 277

After screening, it was observed that the VIA group reported a higher prevalence of symptoms (74%) compared to the HPV group (9%). There was a significant difference among the groups regarding time spent on screening. The out-of-pocket expenditure (OOPE) of women in the VIA group ranged from 0 to \gtrless 6000 (US\$ 0 to 72.1) with a median of \gtrless 120 (IQR \gtrless 60-200) (US\$ 1.4, IQR), which. Time to reach the facility and OOPE did not apply to the HPV group since the screening was conducted in their homes.

285

286 Table 1: Demographic characteristics of screened women in VIA and HPV group

	Women screened by	Women screened by
	VIA (n=95)	HPV (n= 95)
Age (years)		
Mean (SD)	43.6 (<u>+</u> 9.8)	41.3 (±8.5)
Range (yrs)	30-65	30-63

1 (1)	80 (84)
94 (99)	15 (16)
89 (94)	87 (92)
6 (6)	8 (8)
66 (70)	49 (51)
29 (30)	46 (49)
87 (91)	88 (92)
8 (9)	7 (8)
17 (18)	14 (15)
78 (82)	81 (85)
2.44 <u>+</u> 1.5	2.05 <u>+</u> 1.2
70 (74)	8 (9)
25 (26)	87 (91)
86 (90)	NA
9 (10)	
	94 (99) 89 (94) 6 (6) 66 (70) 29 (30) 87 (91) 8 (9) 17 (18) 78 (82) 2.44 ±1.5 70 (74) 25 (26) 86 (90)

Time spent on the screening			
test			
<u><</u> 30 min	85 (89)	95 (100)	
> 30 min	10 (11)	0	
Out of pocket expenditure			
(INR)			
Median {IQR }	120 {60, 200}	NA	

²⁸⁷ Abbreviations- VIA: Visual Inspection using Acetic acid, HPV: Human Papilloma Virus, NA: Not
288 Applicable

- -
- 289

290	The total annual expenditure on screening women for cervical cancer through VIA
291	and HPV DNA tests amounted to ₹5,79,059 (US\$ 6955.4) and ₹28,16,019 (US\$
292	33825), respectively. The details of the annual costs for both screening methods are
293	provided in Table 2. The distribution of the total annual costs for VIA and HPV
294	screening revealed that training (33%) and consumables (30%) comprised the largest
295	proportion of overall expenses in the VIA group. Notably, in the HPV group,
296	approximately 40% (₹11,29,706, US\$ 13569.6) of the total cost was allocated to the
297	purchase of consumables, followed by human resources, which accounted for 30%
298	(₹ 8,55,848 US\$ 10280.1) of the expenditure.

Table 2: Distribution of total annual cost by inputs for VIA and HPV based screening
for cervical cancer during the financial year of 2021-22, Sikkim

	Annual cost in VI	A group	Annual cos	st in HPV
Inputs			gro	սթ
	INR	US\$	(INR)	US\$

Unit cost per test	1,597	19.2	1,271	15.3
No of tests	392		2216	
Total cost	5,79,059	6955.4	28,16,019	33825
Overheads	38,562	463.2	1,35,600	1628.8
Training and meetings	1,91,000	2294.2	1,57,125	1887.3
IEC Material	-	-	22,600	271.5
Consumables	1,76,136	2115.7	11,29,706	13569.6
Human resource	1,52,803	1835.4	8,55,848	10280.1
Furniture & Equipment	12,111	145.5	1,60,859	1932.2
Space/Building	8447	101.5	3,54,281	4255.5

302 Abbreviations- VIA: Visual Inspection using Acetic acid, HPV: Human Papilloma Virus, IEC: Information

303 Education & Communication

304

During the study period, 392 women underwent VIA screening across eleven HWCs.
These HWCs covered a population of 6,031 eligible women, resulting in a screening
coverage of 6.5%. In the HPV group, 2,216 women were screened out of the 6,331
eligible women, yielding a screening coverage of 35%. The unit cost per woman
screened by VIA and HPV was ₹ 1,597 (US\$ 19.2) and ₹ 1,271 (US\$ 15.3),
respectively.

The comparison of EQ-5D-5L index scores of screened women in VIA and HPV groups is tabulated in Table 3. The mean EQ-5D-5L score was significantly higher in the HPV group (1.00 ± 0) than in the VIA group (0.9903 ± 0.02) (p<0.0001). On the eighth day of screening, the EQ-5D-5L scores remained significantly higher in the HPV group (1.000 ± 0) than in the VIA group (0.9972 ± 0.0118) (p=0.02). The overall health score on the day of screening was significantly higher in the HPV group (88.18 ± 5.44) compared to the VIA group (84.4 ± 6.41) , (p<0.0001).

EQ-5D-5L		VIA	HPV	р
Utility score (0-1)	Day 1	0.9903 <u>+</u> 0.0210	1.0000 <u>+</u> 0	<0.0001
(mean score <u>+</u> SD)	Day 8	0.9972 <u>+</u> 0.0118	1.0000 <u>+</u> 0	0.02
Visual Analogue Score (1-100)	Day 1	84.4 <u>+</u> 6.41	88.18 <u>+</u> 5.44	<0.0001
(mean score <u>+</u> SD)	Day 8	89.23 <u>+</u> 3.42	90.75 <u>+</u> 3.66	0.04

319 Table 3: EQ-5D-5L index scores of screened women in VIA and HPV group

321

320

None of the women in the HPV group complained of any deviation from normal in the five dimensions of the EQ-5D-5L. However, in the VIA group, 17% and 7% experienced pain and anxiety, respectively, on day one; on day eight, 3% reported

Abbreviations- VIA: Visual Inspection using Acetic acid, HPV: Human Papilloma Virus

- 325 anxiety. (Supplementary Table A)
- For a duration of 8 days, the QALD was found to be 7.977 for the VIA group and 8
- for the HPV group. Hence the ICER was ₹-14,459 (US\$ 173.7). This is much below
- the WTP threshold for eight days, i.e., \gtrless 4,193 (US\$ 50.4).
- 329 The sensitivity analysis results for changes in the number of women screened using
- the VIA method is shown in Fig. 2A. As the number of screened women decreases,
- the ICER increases. When the number of screened women exceeds 549, HPV self-
- testing ceases to be more cost-effective than VIA. This implies that a screening
 coverage increase of 40% is required for VIA to be considered cost-effective than
 HPV self-testing.

Fig 2A: Sensitivity analysis: Change in ICER value with variation in the

336 number of women screened by VIA

In contrast, Fig. 2B demonstrates the impact of changes in the number of womenscreened by the HPV self-testing method on the ICER. As the number of women

339	screened by HPV self-testing decreases, the ICER increases. Specifically, if the
340	screened numbers fall below 1,665, HPV self-testing ceases to be cost-effective.
341	However, even with a 25% lowering in screened numbers, the HPV self-testing
342	method remains cost-effective.
343	Fig 2B: Sensitivity analysis: Change in ICER value with variation in the
344	number of women screened by HPV
345	
346	The sensitivity analysis results for VIA screening (Fig. 3A) highlighted that training
347	expenses and consumables had the highest impact on the ICER. Conversely, for HPV
348	screening, consumables and human resources were found to have the greatest impact
349	on the ICER (Fig 3B). ICER was below the WTP threshold for all the listed scenarios
350	listed. (Supplementary Table B)
351	Fig 3A: Sensitivity analysis; Key driving factors of ICER with 10% variation
352	in item cost
353	Fig 3B: Sensitivity analysis; Key driving factors of ICER with 25% variation
354	in item cost
355	
356	Discussion
357	The findings of our study indicate that primary HPV screening through self-sampling

is a cost-saving approach for cervical cancer screening, compared to the current recommendation of VIA for population-based screening in India. While the total cost of HPV screening may appear higher, the unit cost per test is substantially lower than

361 VIA, primarily due to the higher screening coverage achieved with HPV screening.

362 HPV self-sampling has been widely recognized for its ability to increase participation
363 in cervical cancer screening as it overcomes various barriers; self-sampling

effectively encourages more individuals to participate in regular screening programs, 364 especially in low and middle-income countries [14,15]. Existing literature indicates 365 that adopting self-sampling approaches can enhance screening participation among 366 women and potentially lead to cost reductions [16]. According to a meta-analysis of 367 29 randomized controlled trials, the utilization of cervical cancer screening services 368 was found to be twice as likely among women who underwent self-sampling 369 370 compared to those who followed standard-of-care screening practices [17]. Women exhibit a preference for self-collection of samples within the convenience of their 371 372 homes, as opposed to visiting healthcare facilities for screening [18]. It was found that there was a high level of compliance among women who opted for this self-373 collection method, with fewer operational challenges encountered during its 374 implementation. Self-sampling presents a distinct opportunity to reach populations 375 376 that are typically difficult to access, making it one of the most viable strategies for post-pandemic screening[19]. Self-sampling for HPV holds the promise of 377 diminishing disparities in cervical screening participation within specific 378 demographics and extending access to underserved and previously unscreened 379 women [20,21]. 380

Although VIA is known as a low-cost test and is recommended in low- and middle-381 382 income countries, the implementation of this subjective test is a major challenge. An 383 Indian randomized controlled trial demonstrated that a single HPV test can effectively decrease the incidence of advanced cervical cancer and associated 384 mortality. In contrast, VIA screening did not exhibit similar benefits in terms of 385 cancer prevention and mortality reduction [22]. The significant hurdle to the 386 widespread implementation of the more precise and efficient HPV screening method 387 arises from the substantial upfront expenses required to establish screening programs. 388

Although cost plays a vital role, it should not be the exclusive factor guiding decisionmaking. It is imperative to consider the well-being of women, along with their overall quality of life and satisfaction [23].

- Our study findings also show significant differences in quality of life between women 392 screened by HPV self-sampling who reported higher utility scores and a better quality 393 of life compared to those who underwent VIA. The higher utility scores indicate that 394 women screened through HPV self-sampling experienced better health-related 395 quality of life, potentially due to reduced anxiety, pain and discomfort associated with 396 397 the self-sampling approach. These results highlight the potential benefits of implementing HPV self-sampling as a preferred screening method, providing women 398 with a more positive screening experience and ultimately contributing to improved 399 400 health outcomes.
- Previous studies have evaluated the cost-effectiveness of HPV self-sampling and VIA 401 for cervical cancer screening [10, 24]. However, unlike these model-based studies, 402 our study uniquely utilizes empirical data, marking the first instance of such an 403 approach in India. An earlier model-based study in India that assessed the cost 404 effectiveness of three screening strategies ie. Papanicolaou test, VIA and clinician 405 based primary HPV testing for cervical cancer screening concluded VIA done every 406 407 5 years to be cost effective approach [10]. However, the study measured the healthrelated quality of life of cervical cancer patients rather than screened women to 408 409 calculate the utility values. This approach failed to capture the immediate change in quality of life associated with the screening procedure itself. In addition, the study 410 did not take into account the building cost of VIA screening as they reported data 411 from camp-based approach. 412

Another study that evaluated cost effectiveness of same three screening strategies 413 within a large cluster randomized trial from rural India (Legood R et al., 2005). The 414 study dismissed HPV to be a cost-effective method for cervical cancer screening. It 415 is important to note that this study accounted for all the costs in 2002, during which 416 HPV testing was relatively new and prices were high, likely due to reduced 417 418 competition in the market. Moreover, the study was conducted in a controlled settings 419 of the trial that would vary from 'real life' situations. The ASPIRE randomized controlled trial included a cost-effectiveness study, which determined that 420 421 community-based self-collected HPV testing is a cost-effective screening strategy [25]. 422

Our study had few limitations. Building costs are typically higher in urban areas 423 compared to rural areas. Differential implementation of HPV testing in urban areas 424 and VIA testing in rural areas could have led to an overestimation of costs associated 425 with the HPV testing strategy and an underestimation of costs associated with the 426 VIA strategy. It is crucial to consider this limitation when interpreting the cost 427 comparisons between the two screening methods. Another limitation of our study 428 originates from the exclusive implementation of HPV screening within the East 429 district of Sikkim [26]. The adoption of HPV screening specifically within urban area 430 in the district has resulted in the inclusion of women who underwent VIA screening 431 solely from rural PHC catchment regions. This specific sampling approach introduces 432 433 a potential bias in the recruitment of participants, which may in turn limit the generalizability of the study findings. 434

In this study we have leveraged empirical data to evaluate the cost-utility of
population-based self-collected HPV testing that is performed at women's homes.
The findings of this study provide a robust support for advocating the adoption and

438	implementation of HPV self-sampling in India. The results indicate that the benefits
439	obtained outweigh the associated costs, establishing it as a cost-effective approach
440	within the provided threshold Further research following a similar framework in
441	diverse settings across India is recommended. These studies would contribute to a
442	more comprehensive understanding of the feasibility of HPV self-sampling as a
443	primary screening method in various regional contexts.
444	

445 **REFERENCES:**


446	1.	IARC. Cervix uteri - Globocan 2020.
447		https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf.
448		Published 2021. Accessed [6 Nov 2023]
449		
450	2.	Operational Guidelines. Prevention Screening and Control of Common Non-
451		Communicable Diseases: Hypertension, Diabetes and Common Cancers (Oral, Breast
452		and Cervix) New Delhi: National Health Mission Ministry of Health and Family
453		Welfare Government of India; 2016. Available from:
454		https://main.mohfw.gov.in/sites/default/files/Operational%20Framework%20Managem
455		ent%20of%20Common%20Cancers_1.pdf accessed [29 August 2023].
456		
457	3.	Shastri SS. Cancer trends and disparities in India: data needs for providing equitable
458		cancer care. Lancet Oncol. 2018;19(10):1260-1261.
459		
460	4.	Mpinga EK and Chastonay P. Patient satisfaction studies and the monitoring of the
461		rightto health: Some thoughts based on a review of the literature. Glob JHealth Sci
462		2011;3:64-7.
463		
464	5.	Gravitt PE, Paul P, Katki HA, Vendantham H, Ramakrishna G, Sudula M, et al.
465		Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening
466		program in a peri-urban community in Andhra Pradesh, India. PLoS One. 2010 Oct
467		28;5(10):e13711.
468		
469	6.	World Health Organization. Global strategy to accelerate the elimination of cervical
470		cancer as a public health problem. Geneva. 2020.
471		https://www.who.int/publications/i/item/9789240014107 Accessed [6 Nov 2023]
472		

473	7.	Bhatla N, Dar L, Patro AR, Kumar P, Kriplani A, Gulati A, et al. Can human
474		papillomavirus DNA testing of self-collected vaginal samples compare with physician-
475		collected cervical samples and cytology for cervical cancer screening in developing
476		countries? Cancer Epidemiol. 2009; 33(6):446-50.
477		
478	8.	Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, et al. Accuracy
479		of human papillomavirus testing on self-collected versus clinician-collected samples: a
480		meta-analysis. Lancet Oncol. 2014;15(2):172-83.
481		
482	9.	Mezei AK, Armstrong HL, Pedersen HN, Campos NG, Mitchell SM, Sekikubo M, et
483		al. Cost-effectiveness of cervical cancer screening methods in low- and middle-income
484		countries: A systematic review. Int J Cancer. 2017; 141(3):437-446.
485		
486	10.	Chauhan AS, Prinja S, Srinivasan R, Rai B, Malliga JS, Jyani G, et al. Cost
487		effectiveness of strategies for cervical cancer prevention in India. PLoS One. 2020 Sep
488		1;15(9):e0238291
489		
490	11.	Korfage IJ, van Ballegooijen M, Wauben B, Looman CW, Habbema JD, Essink-Bot
491		ML. Having a Pap smear, quality of life before and after cervical screening: a
492		questionnaire study. BJOG. 2012;119(8):936-44.
493		
494	12.	EuroQol Research Foundation. EQ-5D-5L User Guide., 2019. Available from:
495		https://euroqol.org/publications/user-guides.
496		
497	13.	Jyani G, Sharma A, Prinja S, Kar SS, Trivedi M, Patro BK, et al. Development of an
498		EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-
499		Level Version EQ-5D Value Set. Value Health. 2022;25(7):1218-1226.
500		

501	14. Di Gennaro G, Licata F, Trovato A, Bianco A. Does self-sampling for human
502	papilloma virus testing have the potential to increase cervical cancer screening? An
503	updated meta-analysis of observational studies and randomized clinical trials. Front
504	Public Health. 2022;10:1003461.
505	
506	15. Gupta S, Palmer C, Bik EM, Cardenas JP, Nuñez H, Kraal L, et al. Self-Sampling for
507	Human Papillomavirus Testing: Increased Cervical Cancer Screening Participation and
508	Incorporation in International Screening Programs. Front Public Health. 2018; 6:77.
509	
510	16. Arrossi S, Thouyaret L, Herrero R, Campanera A, Magdaleno A, Cuberli M, et al.
511	EMA Study team. Effect of self-collection of HPV DNA offered by community health
512	workers at home visits on uptake of screening for cervical cancer (the EMA study): a
513	population-based cluster-randomised trial. Lancet Glob Health. 2015;3(2):e85-94.
514	
515	17. Yeh PT, Kennedy CE, de Vuyst H, Narasimhan M. Self-sampling for human
516	papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Glob
517	Health. 2019;4(3): e001351.
518	
519	18. Kilfoyle KA, Des Marais AC, Ngo MA, Romocki L, Richman AR, Barclay L, Brewer
520	NT, Rahangdale L, Smith JS. Preference for Human Papillomavirus Self-Collection
521	and Papanicolaou: Survey of Underscreened Women in North Carolina. J Low Genit
522	Tract Dis. 2018;22(4):302-310.
523	
524	19. Lozar T, Nagvekar R, Rohrer C, Dube Mandishora RS, Ivanus U, Fitzpatrick MB.
525	Cervical Cancer Screening Post pandemic: Self-Sampling Opportunities to Accelerate
526	the Elimination of Cervical Cancer. Int J Women's Health. 2021; 13:841-859.
527	

528	20. Levinson KL, Jernigan AM, Flocke SA, Tergas AI, Gunderson CC, Huh WK, et al.
529	Intimate Partner Violence and Barriers to Cervical Cancer Screening: A Gynecologic
530	Oncology Fellow Research Network Study. J Low Genit Tract Dis. 2016;20(1):47-51
531	
532	21. Berner AM, Connolly DJ, Pinnell I, Wolton A, MacNaughton A, Challen C, et al.
533	Attitudes of transgender men and non-binary people to cervical screening: a cross-
534	sectional mixed-methods study in the UK. Br J Gen Pract. 2021;71(709):e614-e625.
535	
536	22. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al.
537	HPV screening for cervical cancer in rural India. N Engl J Med. 2009; 360(14):1385-
538	94.
539	
540	23. Sawaya GF, Sanstead E, Alarid-Escudero F, Smith-McCune K, Gregorich SE,
541	Silverberg MJ, Leyden W, Huchko MJ, Kuppermann M, Kulasingam S. Estimated
542	Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer
543	Screening Strategies: A Cost-effectiveness Analysis. JAMA Intern Med.
544	2019;179(7):867-878.
545	
546	24. Legood R, Gray AM, Mahé C, Wolstenholme J, Jayant K, Nene BM, et al. Screening
547	for cervical cancer in India: How much will it cost? A trial-based analysis of the cost
548	per case detected. Int J Cancer. 2005;117(6):981-7.
549	
550	25. Mezei AK, Pedersen HN, Sy S, Regan C, Mitchell-Foster SM, Byamugisha J, et al.
551	Community-based HPV self-collection versus visual inspection with acetic acid in
552	Uganda: a cost-effectiveness analysis of the ASPIRE trial. BMJ Open.
553	2018;8(6):e020484.
554	

555	26. Dhanasekaran K, Tamang H, Pradhan S, Lhamu R, Hariprasad R. Challenges in setting
556	up a primary human papillomavirus-DNA testing facility in a lower and middle income
557	country: lessons learned from a pilot programme. Ecancermedicalscience. 2022;
558	16:1492.
559	
560	
561	Supplimentary file:
562	a. Table A: EQ-5D-5L frequencies and proportions reported by dimensions and
563	level
564	b. Table B: Comparison of ICER and unit cost for different cervical cancer
565	screening scenarios
566	c. Fig A: Flow of screening process in HPV and VIA group






Figure 2A




Figure 2B




Figure 3A




Figure 3B